Patients with primary Merkel cell carcinoma are at an increased risk of developing a secondary skin cancer vs other malignancies.

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

The strong results of KEYNOTE-689 and likely FDA approval of pembrolizumab for perioperative HNSCC raise both concerns and ...

New data show strong overall survival rates, building on previously reported outcomes with efti plus pembrolizumab for head ...

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

Hunan, China – December 9, 2024: A mischievous dog snatched a sausage from a toddler's hands in seconds. The boy burst into ...

Doctors removed her cancerous tongue and, using a flap of skin from her forearm, created a new tongue. Her grafted skin had ...

In in vitro and in vivo preclinical studies, ficerafusp alfa + a KRAS-G12C inhibitor (G12Ci) was shown to be more effective than G12Ci alone, with G12Ci-resistant lung cancer cells remaining ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...